Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases

MT Newswires Live04-01

Apellis Pharmaceuticals (APLS) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Empaveli, or pegcetacoplan, to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, both rare kidney diseases.

The company said the application is based on results from a late-stage trial that achieved its primary endpoint of "statistically significant" reduction in proteinuria and indicated stabilization of kidney function in patients treated with Empaveli.

The agency granted the application Priority Review and scheduled a decision date of July 28, Apellis said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2524111996?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-01 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524111996","market":"hk","top_or_hot":-1,"title":"Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases","media":"MT Newswires Live","content":"<html><body><p> Apellis Pharmaceuticals (APLS) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Empaveli, or pegcetacoplan, to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, both rare kidney diseases.</p><p>The company said the application is based on results from a late-stage trial that achieved its primary endpoint of \"statistically significant\" reduction in proteinuria and indicated stabilization of kidney function in patients treated with Empaveli.</p><p>The agency granted the application Priority Review and scheduled a decision date of July 28, Apellis said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-01 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Apellis Pharmaceuticals (APLS) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Empaveli, or pegcetacoplan, to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, both rare kidney diseases.</p><p>The company said the application is based on results from a late-stage trial that achieved its primary endpoint of \"statistically significant\" reduction in proteinuria and indicated stabilization of kidney function in patients treated with Empaveli.</p><p>The agency granted the application Priority Review and scheduled a decision date of July 28, Apellis said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2524111996","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524111996","pubTimestamp":1743512726,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Apellis Pharmaceuticals (APLS) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Empaveli, or pegcetacoplan, to treat C3 glomerulopathy and p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4505":"高瓴资本持仓","BK4139":"生物科技","APLS":"Apellis Pharmaceuticals Inc."},"translate_title":"Apellis Pharmaceuticals称美国FDA授予Empaveli罕见肾病申请优先审评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLS":0.9},"content_text":"Apellis Pharmaceuticals (APLS) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Empaveli, or pegcetacoplan, to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, both rare kidney diseases.The company said the application is based on results from a late-stage trial that achieved its primary endpoint of \"statistically significant\" reduction in proteinuria and indicated stabilization of kidney function in patients treated with Empaveli.The agency granted the application Priority Review and scheduled a decision date of July 28, Apellis said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2524111996","isCrawlerRequest":true}